Directed evolution of adeno-associated virus (AAV) yields mutant vectors that can evade neutralizing antibodies.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Recent progress and considerations for AAV gene therapies targeting the central nervous system
Journal of Neurodevelopmental Disorders Open Access 18 May 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ness, J.E. et al. Adv. Protein Chem. 55, 261–292 (2000).
Soong, N.W. et al. Nat. Genet. 25, 436–439 (2000).
Maheshri, N. et al. Nat. Biotech. 24, 198–204 (2006).
Gao, G. et al. Curr. Gene Ther. 5, 285–297 (2005).
Romano, G., Drug News Perspect. 18, 311–316 (2005).
Duan, D. et al. Mol. Ther. 4, 383–391 (2001).
Muzyczka, N. & Warrington, K.H. Jr. Hum. Gene Ther. 16, 408–416 (2005).
Zaiss, A.K. & Muruve, D.A. Curr. Gene Ther. 5, 323–331 (2005).
Wu, P. et al. J. Virol. 74, 8635–8647 (2000).
Lochrie, M.A. et al. J. Virol. 80, 821–834 (2005).
Moskalenko, M. et al. J. Virol. 74, 1761–1766 (2000).
Padron, E. et al. J. Virol. 79, 5047–5058 (2005).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Asokan, A., Samulski, R. AAV does the shuffle. Nat Biotechnol 24, 158–160 (2006). https://doi.org/10.1038/nbt0206-158
Issue Date:
DOI: https://doi.org/10.1038/nbt0206-158
This article is cited by
-
IgG-cleavage protein allows therapeutic AAV gene delivery in passively immunized MPS IIIA mice
Gene Therapy (2023)
-
Recent progress and considerations for AAV gene therapies targeting the central nervous system
Journal of Neurodevelopmental Disorders (2018)
-
Characterization of Genome Integrity for Oversized Recombinant AAV Vector
Molecular Therapy (2010)